MiniMed™ 670G System European Real-World Data Shows 73% Time in Range, Beyond Recommended Targets
DUBLIN, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions today announced real-world clinical outcomes on European patients for the MiniMed™ 670G system. The European data showed an average Time in Range of 73%1, a result that exceeds the recommended Time in Range consensus guidelines of 70% that were recently published2. The real-world data of 4,369 patients showed an average estimated HbA1c of 6.9%*1, also surpasses the recommended target.3
The SmartGuard™ Auto Mode feature in the MiniMed 670G system automates and personalizes the delivery of basal insulin 24 hours a day. This system is the only commercially available technology in the world to provide protection from highs and lows, and proactively drive increased Time in Range by consistently guiding to the target of 120 mg/dL (6.7mmol/L) throughout the day.4,5
“The Time in Range clinical guidelines recommend that the target of effective diabetes management is the range of 70-180 mg/dL (3.9-10mmol/L) for at least 70% of time. By exceeding this target in a real-world setting, in its first year of use in Europe, the MiniMed 670G system provides additional reassurance to healthcare professionals and their patients as the highest standard of care for diabetes available today,”1,3 said Johan Jendle, M.D., Ph.D., professor at the Institute of Medical Sciences, University Hospital Örebro, Sweden.
"The European real-world data adds to a growing body of evidence that further demonstrates that the MiniMed 670G system improves Time in Range and exceeds recommended clinical targets. This new data demonstrates similar results to the ones of the controlled pivotal trials of the system4,5,6. This is particularly impressive considering these results were achieved in an uncontrolled environment," said Dr. Robert Vigersky, chief medical officer for the Diabetes Group at Medtronic. “The fact that this real-world data exceeds the Time in Range target demonstrates the strong positive outcomes the MiniMed 670G system can drive, also by contributing to the prevention of short and long-term complications of this chronic disease.”1,3
“My life has changed significantly, since I started using the MiniMed 670G system last year,” said Elin Holmlund, 35 years old, from Sweden. “The SmartGuard Auto Mode feature allows me to live more freely, knowing I don’t need to permanently think about the next low or high, and what I can do to try to prevent it. The system takes some of that emotional burden away from me. Since I started using the system, I have fewer lows and highs. My Time in Range is consistently on track and so is my life.”
The MiniMed 670G system real-world European data further demonstrates the system’s ability to provide protection from low sugar levels with people spending on average just 2.3% of time below 70 mg/dL (3.9 mmol/L)1. This surpasses the recommended target of less than 4% of time below 70 mg/dL (3.9 mmol/L)2.
The MiniMed 670G system is now being used by more than 200,000 people worldwide, including more than an estimated 10,000 from across Europe.7 Medtronic began the commercialization of the MiniMed 670G system across the Europe, Middle East and Africa (EMEA) region in October 2018, and the system is currently available in seventeen countries. Most recently, on August 29, 2019, the company secured reimbursement for the MiniMed 670G system with the German Federal Association of the Statutory Health Insurances (GKV-SV).
Time in Range
Time in Range refers to the percentage of time people with diabetes spend in the optimal glycemic range of 70-180 mg/dL (3.9-10 mmol/L). The goal with diabetes management is to increase time spent in this target range and to minimize high and low sugar levels, which can lead to both immediate and long-term complications such as damage to blood vessels - increasing the risk of coronary artery disease and stroke. Damage to blood vessels can also lead to loss of vision, kidney disease, and nerve damage.
About the Diabetes Group at Medtronic
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
1. Medtronic data on file. MiniMed 670G data uploaded voluntarily by 4,369 users in Europe to CareLinkTM Personal, from 01 October 2018 to 14 August 2019
2. Battelino T, et al. Diabetes Care 2019 Aug; 42(8): 1593-1603.
3. ADA Guidelines of A1C<7.0 –www.Diabetes.org.
4. Bergenstal, R. M. et al. Jama. 2016 ; 316 (13) : 1407 – 1408.
5. Garg SK et al. Diabetes Technol Ther. 2017 Mar;19(3):155-163
6. Forlenza GP, et al. Diabetes Technol Ther. 2018;21(1):11-19.
7. Data on file: Estimated patients numbers based upon shipment data 26thAugust 2019
**Estimated HbA1C based on reported mean glucose values at end of study 159mg/dL (8.8 mmol/L) and 154mg/dL (8.6 mmol/L). Calculated using JAEB https://www.jaeb.org/gmi/.
See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information,contact your local Medtronic representative.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Nexstim Abp: Preliminärt utfall av den lyckade företrädesemissionen1.6.2020 19:30:00 CEST | Pressemelding
Företagsmeddelande, insiderinformation, Helsingfors 1 juni 2020 kl. 20.30 (EEST) Nexstim Abp: Preliminärt utfall av den lyckade företrädesemissionen FÅR EJ PUBLICERAS ELLER SPRIDAS DIREKT ELLER INDIREKT I FÖRENTA STATERNA, AUSTRALIEN, SYDAFRIKA, HONGKONG, JAPAN, KANADA, SINGAPORE ELLER NÅGON ANNAN STAT DÄR SPRIDNINGEN ELLER PUBLICERINGEN STRIDER MOT LAGEN. Teckningstiden för Nexstim Abp:s (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) företrädesemission om cirka 2,3 miljoner euro (”emissionen”) avslutades 25 maj 2020 i Sverige och 27 maj 2020 i Finland. Enligt det preliminära emissionsutfallet övertecknades emissionen och cirka 273 procent av de tilldelade aktierna tecknades. Av de tilldelade 376 719 780 nya aktierna (”emissionsaktierna”) tecknades 336 033 654 emissionsaktier (cirka 89,2 procent av emissionsaktierna) med företrädesrätt och 40 686 126 emissionsaktier (cirka 10,8 procent av emissionsaktierna) tilldelas i enlighet med emissionsvillkoren. Enligt det preliminära emissio
Nexstim Plc: Preliminary results of the successful rights issue1.6.2020 19:30:00 CEST | Press release
Company announcement, inside information, Helsinki, 1 June 2020 at 8:30 pm (EEST) Nexstim Plc: Preliminary results of the successful rights issue NOT FOR PUBLICATION OR DISTRIBUTION, EITHER DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, SOUTH AFRICA, HONG KONG, JAPAN, CANADA OR SINGAPORE, OR IN ANY OTHER COUNTRY WHERE PUBLICATION OR DISTRIBUTION WOULD BE AGAINST THE LAW. The subscription period of Nexstim Plc’s (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “the Company”) rights issue of approximately EUR 2.3 million (“the Share Issue”) ended on 25 May 2020 in Sweden and on 27 May 2020 in Finland. The preliminary results indicate that the Share Issue was oversubscribed and a total of 273% shares were subscribed for of the shares offered. Of the 376,719,780 new shares offered in the Share Issue (“the Offer Shares”), 336,033,654 Offer Shares (approximately 89,2% of the Offer Shares) were subscribed using subscription rights which means that 40,686,126 Offer Shares (approximately 10.8% of
Kinnevik: Valberedning inför årsstämman 20211.6.2020 17:00:00 CEST | Pressemelding
I enlighet med beslutet vid årsstämman 2020 i Kinnevik AB (publ) (”Kinnevik”) har en valberedning sammankallats, bestående av ledamöter utsedda av Kinneviks röstmässigt största aktieägare. Valberedningen består av Cristina Stenbeck utsedd av Verdere S.à r.l. och CMS Sapere Aude Trust, Hugo Stenbeck utsedd av Alces Maximus LLC, James Anderson utsedd av Baillie Gifford, Anders Oscarsson utsedd av AMF Försäkring & Fonder, Marie Klingspor och Ramsay Brufer utsedd av Alecta. Anders Oscarsson har utsetts till ordförande i valberedningen. Information om valberedningens arbete finns på Kinneviks hemsida, www.kinnevik.com. Aktieägare som önskar lämna förslag till valberedningen kan göra det i skrift till firstname.lastname@example.org eller till Valberedningen, Kinnevik AB, Box 2094, 103 13 Stockholm. För ytterligare information, besök www.kinnevik.com eller kontakta: Torun Litzén, Informations- och IR-chef Telefon +46 (0)70 762 00 50 Email email@example.com Kinnevik är ett sektorfokuserat investmentbolag s
Kinnevik: Nomination committee ahead of the 2021 Annual General Meeting1.6.2020 17:00:00 CEST | Press release
In accordance with the resolution of the 2020 Annual General Meeting in Kinnevik AB (publ) (“Kinnevik”), a Nomination Committee has been convened comprising members appointed by Kinnevik’s largest shareholders in terms of voting interest. The Nomination Committee comprises Cristina Stenbeck appointed by Verdere S.à r.l. and CMS Sapere Aude Trust, Hugo Stenbeck appointed by Alces Maximus LLC, James Anderson appointed by Baillie Gifford, Anders Oscarsson appointed by AMF Insurance & Funds, Marie Klingspor and Ramsay Brufer appointed by Alecta. Anders Oscarsson has been appointed Committee Chairman. Information about the work of the Nomination Committee can be found on Kinnevik’s website at www.kinnevik.com. Shareholders wishing to submit proposals to the Nomination Committee can do so in writing to firstname.lastname@example.org or to the Nomination Committee, Kinnevik AB, P.O. Box 2094, SE-103 13 Stockholm Sweden. For further information, visit www.kinnevik.com or contact: Torun Litzén, Director Inve
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER1.6.2020 16:20:00 CEST | Press release
Bid procedure on 3 June 2020 Certificate:Commercial paper issued in SEK by non-financial companies with a registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the maturity date on 3 December 2020 at the latest. Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 25 May 2020.Bids:Counterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date:Wednesday 3 June 2020Bid time:0900-0930 hours (CEST) on the Bid dateRequested volume: (corresponding nominal amount)SEK 4 billion Highest permitted bid volume: (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SE
Real People Investment Holdings Limited – Appointment of Director1.6.2020 15:00:00 CEST | Press release
The board of Real People Investment Holdings Limited has elected to appoint Mr Ralph Buddle as a non-executive director of the company, with effect from 1 June 2020. Mr Buddle is an experienced senior executive and chartered accountant with 35 years’ experience in retail and FMCG. With a background in corporate finance, M&A and strategy, he also has significant investor relations and corporate governance experience within the JSE Top-40 listed environment. * * * * * * * For further information, please contact: Neil Grobbelaar, Group Chief Executive Officer Email: email@example.com Phone number: +27 82 772 5481 The information was submitted for publication, through the agency of the contact person set out above, on June 1st, 2020 at 15:00 CET Attachment RPIH Press Release - Appointment of director 20200528